516 related articles for article (PubMed ID: 26043236)
1. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters.
Kawamura K; Yamasaki T; Konno F; Yui J; Hatori A; Yanamoto K; Wakizaka H; Ogawa M; Yoshida Y; Nengaki N; Fukumura T; Zhang MR
Bioorg Med Chem; 2011 Jan; 19(2):861-70. PubMed ID: 21185730
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.
Raaphorst RM; Luurtsema G; Schuit RC; Kooijman EJM; Elsinga PH; Lammertsma AA; Windhorst AD
ACS Chem Neurosci; 2017 Sep; 8(9):1925-1936. PubMed ID: 28650628
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
Bauer F; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Mairinger S; Dörner B; Löscher W; Müller M; Erker T; Langer O
Bioorg Med Chem; 2010 Aug; 18(15):5489-97. PubMed ID: 20621487
[TBL] [Abstract][Full Text] [Related]
5. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
6. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
8. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.
Dörner B; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Müllauer J; Bauer F; Mairinger S; Löscher W; Miller DW; Chiba P; Müller M; Erker T; Langer O
Bioorg Med Chem; 2011 Apr; 19(7):2190-8. PubMed ID: 21419632
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [
Savolainen H; Windhorst AD; Elsinga PH; Cantore M; Colabufo NA; Willemsen AT; Luurtsema G
J Cereb Blood Flow Metab; 2017 Apr; 37(4):1286-1298. PubMed ID: 27354093
[TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
Mairinger S; Langer O; Kuntner C; Wanek T; Bankstahl JP; Bankstahl M; Stanek J; Dörner B; Bauer F; Baumgartner C; Löscher W; Erker T; Müller M
Nucl Med Biol; 2010 Jul; 37(5):637-44. PubMed ID: 20610168
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
15. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
[TBL] [Abstract][Full Text] [Related]
16. Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.
Tournier N; Saba W; Goutal S; Gervais P; Valette H; Scherrmann JM; Bottlaender M; Cisternino S
AAPS J; 2015 May; 17(3):652-9. PubMed ID: 25716150
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
18. [11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.
Asakawa C; Ogawa M; Kumata K; Fujinaga M; Kato K; Yamasaki T; Yui J; Kawamura K; Hatori A; Fukumura T; Zhang MR
Bioorg Med Chem Lett; 2011 Apr; 21(8):2220-3. PubMed ID: 21419625
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Shaik N; Giri N; Pan G; Elmquist WF
Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
[TBL] [Abstract][Full Text] [Related]
20. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]